Stroke drug trial halted after just 2 patients
NCT ID NCT06107725
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study aimed to see if the antibiotic minocycline could improve outcomes for people having a stroke. Participants were to receive either standard care alone or standard care plus minocycline for five days. However, the trial was stopped early after enrolling only 2 people, so it could not provide meaningful results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maimonides Medical Center
Brooklyn, New York, 11219, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Minocycline (an antibiotic with potential nerve-protecting effects)
What this could lead to
If it worked, minocycline might reduce death and disability after a stroke when added to standard care.
What could go wrong
The trial was terminated early with only 2 participants, so no reliable conclusions can be drawn. Minocycline's benefits for stroke remain unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.